Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

AIM: (177)Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior to the FDA approval of Lu-177 showed favorable ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hentzen, Stijn, Mehta, Kathan, Al-Rajabi, Raed Moh’d Taiseer, Saeed, Anwaar, Baranda, Joaquina Celebre, Williamson, Stephen K., Sun, Weijing, Kasi, Anup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344897/
https://www.ncbi.nlm.nih.gov/pubmed/37455826
http://dx.doi.org/10.37349/etat.2023.00141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344897/
https://www.ncbi.nlm.nih.gov/pubmed/37455826
http://dx.doi.org/10.37349/etat.2023.00141

Ejemplares similares